ClinicalTrials.gg
RecruitingNCT06575738PRESSUREUpdated Jul 15, 2026

Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

A Phase 1 interventional study of Injectable semaglutide or injectable tirzepatide and Standard postoperative care in Obesity, Adolescent Obesity and Body-Weight Trajectory, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 12 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Primary conditionPediatric ObesityRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pediatric Obesity
Why
  1. The study's listed conditions name Pediatric Obesity, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Colorado, Denver · Phase 1, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
12 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Pediatric Obesity by University of Colorado, Denver — 3 open to participants now, 5 under way, none of them phase 3. Pediatric Obesity · University of Colorado, Denver.

Planned enrollment
9th of 11
40 · median 100
Started
2024
with 1 other
Phase 1
Only one
of the 14
Registered
13th of 14
by date

Among the 14 studies in Pediatric Obesity by University of Colorado, Denver, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 1, and was the 13th registered.

Pediatric Obesity

1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.

Browse Pediatric Obesity studies →

Open to participants now

3 of the 14 studies in Pediatric Obesity by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.

This study: 12 Years to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pediatric Obesity by University of Colorado, Denver, or all of them as a file.
02

Study summary

The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide or tirzepatide) can help people 12 to 24 years old who, between 6 and 24 months after bariatric surgery, have not lost as much weight as expected.

03

Conditions studied

  • Obesity
  • Adolescent Obesity
  • Body-Weight Trajectory
  • Weight Loss Trajectory
  • Bariatric Surgery
  • Anti-obesity Agents

Browse trials for

Keywords

  • Obesity
  • Anti-obesity medication
  • Bariatric Surgery
  • Bariatric Surgery Post Operative Outcomes
  • Semaglutide
  • Sleeve gastrectomy
04

In context

Pediatric Obesity Reclassified

1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.

This study's planned enrollment of 40 is below the median of 100 across 872 interventional studies indexed under Pediatric Obesity.

Browse Pediatric Obesity studies →

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.

Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.

Compared within Pediatric Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Observation Phase

Inclusion Criteria:

  • Signed and dated form
  • Willingness to comply with all study procedures and availability for the duration of the study
  • Male or female biological sex, age 12 through 24 years
  • In the preoperative pathway for vertical sleeve gastrectomy

Exclusion Criteria:

  • Planned Roux-en-Y gastric bypass
  • Hypothalamic obesity
  • Type 2 Diabetes
  • Current use of oral (i.e. within 10 days of baseline visit)
  • Current use of insulin

Intervention/Treatment Phase

Inclusion Criteria:

  • Signed and dated informed consent form
  • Status post vertical sleeve gastrectomy
  • Male or female biological sex, age 12 through 24 years
  • Meeting minimum nutrition goals
  • Obesity: age 12-17 years: ≥95th%ile for age/sex \| age 18-24 years: BMI ≥ 30kg/m\^2
  • If entering the Intervention phase from the Observational phase: ≤22% BMI loss at 6-24 months postop
  • If entering the Intervention phase from the existing patient pool: ≤22% BMI loss at 6-24 months postop

Exclusion Criteria:

  • Surgically correctable cause of suboptimal postoperative weight loss
  • Known to any component of semaglutide
  • Personal or family history of medullary thyroid carcinoma
  • Personal history of multiple endocrine neoplasia type 2
  • Hypothalamic Obesity
  • Type 2 Diabetes
  • History of pancreatitis
  • Uncontrolled hypertension
  • arrhythmia or heart disease that could be exacerbated by increased heart rate
  • Malignant neoplasm within the last 5 years
  • Untreated thyroid disorder
  • Tanner Stage 1
  • Baseline (ALT) or aspartate aminotransferase (AST) ≥ 5x
  • Baseline Creatinine >1.2mg/dL
  • Active treatment for bulimia nervosa
  • Active major psychiatric disorder limiting informed consent
  • Suicidal ideation of type 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)
  • Intentional self-harm within the previous 1 month
  • Severe unmanaged depression, defined by Center for Epidemiological Studies Depression (CESD) score of 26 or greater and by clinical evaluation
  • Recent change to concomitant medications for hypertension, dyslipidemia, depression or anxiety (\<4 weeks prior to enrollment)
  • Use of oral glucocorticoids (within 10 days of baseline visit)
  • Use of metformin (within 3 months of baseline visit)
  • Use of insulin secretagogues (within 4 half-lives of the medication of baseline visit)
  • Current use of insulin
  • Use of anti-obesity medications (within 4 half-lives of the medication of baseline visit)
  • Current pregnancy
  • For females of : Plan to become pregnant in the next 8 months
  • For females of reproductive potential: Not on (i.e. two forms of birth control for example oral birth control pills and condoms) for at least 1 month prior to enrollment and agreement to use these during study participation and for an additional 8 weeks after the final dose of study medication
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    Observational

    Participants complete a set of standardized measures before bariatric surgery, 3 months postoperatively, and 6 months postoperatively.

  • Experimental
    Active Medication + Standard Postoperative Care

    Participants can be enrolled between 6 and 24 months postoperatively and will receive usual interdisciplinary postoperative care plus weekly subcutaneous injectable semaglutide or tirzepatide for 26 weeks. Initial dose is 0.25mg (semaglutide) or 2.5mg (tirzepatide) and is escalated every 4 weeks as tolerated up to the max dose of 2.4mg for semaglutide or 15mg for tirzepatide for a total exposure of 26 weeks.

    Drug: Injectable semaglutide or injectable tirzepatide · Behavioral: Standard postoperative care

  • Active comparator
    Standard Postoperative Care

    Participants can be enrolled between 6 to 24 months postoperatively and will receive usual interdisciplinary postoperative care.

    Behavioral: Standard postoperative care

Interventions

  • DrugInjectable semaglutide or injectable tirzepatide

    Subcutaneous weekly injectable medication

  • BehavioralStandard postoperative care

    Standard postoperative care consists of behaviorally-focused interventions delivered by the interdisciplinary Bariatric Surgery Center team targeting nutrition, physical activity, sleep, and mental health at standard postoperative intervals.

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

07

What researchers measure

Primary outcomes

  1. Observational phase: Change in fasting glucagon-like peptide-1 (GLP1), measured by blood levels

    GLP1 levels are measured prior to an oral mixed meal tolerance test

    Time frame: Baseline, 6 months postoperatively

  2. Observational phase: Change in stimulated glucagon-like peptide-1 (GLP1), measured by blood levels

    GLP1 levels are measured during an oral mixed meal tolerance test

    Time frame: Baseline, 6 months postoperatively

  3. Observational phase: Change in insulin sensitivity (IS), measured by fasting blood insulin levels

    Fasting insulin levels are measured. IS is defined as 1/fasting insulin

    Time frame: Baseline, 6 months postoperatively

  4. Observational phase: Change in percent fat free mass (FFM), measured by whole body dual-energy X-ray absorptiometry (DXA)

    Percent FFM is calculated as (1-Percent Fat Mass) from DXA

    Time frame: Baseline, 6 months postoperatively

  5. Observational phase: Change in resting metabolic rate (RMR), measured by canopy indirect calorimetry

    RMR from canopy indirect calorimetry

    Time frame: Baseline, 6 months postoperatively

  6. Observational phase: Change in 24 hour systolic blood pressure (BP), measured by ambulatory BP monitor

    Mean 24 hour systolic BP

    Time frame: Baseline, 6 months postoperatively

  7. Observational phase: Change in indexed left ventricular mass (g/m to the 2.7th power), measured by echocardiogram

    Resting supine 2-dimensional echocardiogram

    Time frame: Baseline, 6 months postoperatively

  8. Intervention phase: Change in BMI

    \[(BMI at 26 weeks-Weight at Intervention Baseline)\]/(BMI at Intervention Baseline)\] \* 100

    Time frame: Baseline, 26 weeks

Secondary outcomes

  1. Change in fasting glucagon-like peptide-1 (GLP1), measured by blood levels

    GLP1 levels are measured prior to an oral mixed meal tolerance test

    Time frame: Baseline, 3 months postoperatively

  2. Change in stimulated glucagon-like peptide-1 (GLP1), measured by blood levels

    GLP1 levels are measured during an oral mixed meal tolerance test

    Time frame: Baseline, 3 months postoperatively

  3. Change in fasting Peptide YY (PYY), measured by blood levels

    PYY levels are measured prior to an oral mixed meal tolerance test

    Time frame: Baseline, 3 months postoperatively

  4. Change in fasting Peptide YY (PYY), measured by blood levels

    PYY levels are measured prior to an oral mixed meal tolerance test

    Time frame: Baseline, 6 months postoperatively

  5. Change in stimulated Peptide YY (PYY), measured by blood levels

    Plasma PYY levels are measured during an oral mixed meal tolerance test

    Time frame: Baseline, 3 months postoperatively

  6. Change in stimulated Peptide YY (PYY), measured by blood levels

    Plasma PYY levels are measured during an oral mixed meal tolerance test

    Time frame: Baseline, 6 months postoperatively

  7. Change in fasting ghrelin, measured by blood levels

    Ghrelin levels are measured prior to an oral mixed meal tolerance test

    Time frame: Baseline, 3 months postoperatively

  8. Change in fasting ghrelin, measured by blood levels

    Ghrelin levels are measured prior to an oral mixed meal tolerance test

    Time frame: Baseline, 6 months postoperatively

  9. Change in stimulated ghrelin, measured by blood levels

    Ghrelin levels are measured during an oral mixed meal tolerance test

    Time frame: Baseline, 3 months postoperatively

  10. Change in stimulated ghrelin, measured by blood levels

    Ghrelin levels are measured during an oral mixed meal tolerance test

    Time frame: Baseline, 6 months postoperatively

  11. Change in insulin sensitivity (IS), measured by fasting blood insulin levels

    Fasting insulin levels are measured. IS is defined as 1/fasting insulin

    Time frame: Baseline, 3 months postoperatively

  12. Change in percent fat free mass (FFM), measured by whole body dual-energy X-ray absorptiometry (DXA)

    Percent FFM is calculated as (1-Percent Fat Mass) from DXA

    Time frame: Baseline, 3 months postoperatively

  13. Change in resting metabolic rate (RMR), measured by canopy indirect calorimetry

    RMR from canopy indirect calorimetry

    Time frame: Baseline, 3 months postoperatively

  14. Change in 24 hour systolic blood pressure (BP), measured by ambulatory BP monitor

    Mean 24 hour systolic BP

    Time frame: Baseline, 3 months postoperatively

  15. Change in indexed left ventricular mass (g/m to the 2.7th power), measured by echocardiogram

    Resting supine 2-dimensional echocardiogram

    Time frame: Baseline, 3 months postoperatively

  16. Intervention Phase: Eligibility rate

    (Patients meeting inclusion and exclusion criteria/Total patients screened)\*100

    Time frame: Up to 150 weeks

  17. Intervention Phase: Enrollment rate

    (Participants enrolled/Patients eligible)\*100

    Time frame: Up to 154 weeks

  18. Intervention Phase: Retention rate

    (Participants completing all intervention visits/Patients enrolled)\*100

    Time frame: Up to 184 weeks

  19. Intervention Phase: Mean maximum tolerated semaglutide dose or tirzepatide dose

    Mean maximum tolerated dose (mg) of weekly injectable semaglutide or tirzepatide

    Time frame: Baseline, 26 weeks

  20. Intervention Phase: Number of participants with at least one serious adverse event (AE) in the active medication group, measured by a count

    Individual participants with serious AEs will be counted

    Time frame: Up to 30 weeks

  21. Intervention Phase: Number of participants with an adverse event (AE) that leads to discontinuation of the medication, measured by a count

    Participants experiencing an AE that leads to medication discontinuation will be counted

    Time frame: Up to 30 weeks

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2024
First posted
Aug 28, 2024
StartActual
Oct 11, 2024
Primary completionEst.
Sep 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06575738
Responsible party
Sponsor
First posted
Aug 28, 2024
Start date
Oct 11, 2024
Primary completion
Sep 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Jaime Moore, MD MPH
Contact
jaime.moore@cuanschutz.edu
303-724-8419
Jaime Moore, MD MPH
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Semaglutide · Tirzepatide

Start the discussion